Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Face to face with the IFPMA's Dr Harvey Bale: "Coordination with attitude"

This article was originally published in Scrip

Executive Summary

He has now retired as director-general of theIFPMA, the international federation of pharmaceutical manufacturers & associations. But just before he left, I met Dr Harvey Bale for a chat in a central London hotel. He was in fact waiting for me in the lobby of the hotel five minutes before the allotted time, looking dapper and expectant.

You may also be interested in...



Genmab Accelerates Priority Candidates, Ends Enapotamab Vedotin Development

Denmark’s biotech Genmab has dropped the AXL targeted antibody-drug conjugate, enapotamab vedotin from early clinical development, and is focusing its resources on other therapeutic programs.

Pipeline Watch: Phase III Readouts In Liver Diseases, COVID-19

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharvaris Oral HAE Candidate Heading Into Phase II In 2021

European biotech Pharvaris has received series C funding to support its novel potential therapy for hereditary angioedema, in a competitive sector of drug development.

Topics

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel